
As more patents make their way through IPRs, the balance of how the pharmaceutical industry selects between IPRs and district court litigation will likely evolve.
Dr. Erica Pascal is a partner in DLA Piper’s Patent Litigation practice

Published: July 24th 2015 | Updated: